Another study investigated Fezolinetant, a neurokinin (NK)-receptor antagonist commonly used to treat symptoms of menopause, and found a significant reduction in hyperandrogenism and LH-to-FSH ratio [21]. This evidence concerns the gene BRD2 and hyperandrogenism.